In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.
An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.
A highly cited paper on Alzheimer’s disease may have been purposely manipulated.
If replicated in humans, these findings could mean that targeting or boosting the circadian rhythm in Alzheimer’s patients, could help with managing the disease
PET scans using a special tracer can pick up ‘tau tangles’ in the brain.
Clinical trials of the drug have shown mixed results.
The first drug targeting Alzheimer’s disease has been approved in 20 years – but its approval isn’t based on substantial evidence.
It was first officially described 115 years ago, but we still do not have a cure for Alzheimer’s disease. The human brain is extremely complex, and Alzheimer’s is its most complex disease.
The researchers developed a molecule which works to stop toxic proteins from building up in the brain.
We now have the technology to identify people who are on a fast track to developing dementia.
Protein tangles have been blamed for causing Alzheimer’s – but drugs that target them keep failing.
An important cell function called endocytosis is revealing a lot about how Alzheimer’s develops.